{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:38:55Z","timestamp":1790419135850,"version":"4.1.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T00:00:00Z","timestamp":1640304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T00:00:00Z","timestamp":1640304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Microbiol Biotechnol"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec><jats:title>Abstract<\/jats:title><jats:p>Different serotypes of botulinum toxins (BoNTs) act upon different types of SNARE proteins. This property is used in aesthetic medicine to treat certain eye disorders such as crossed eyes (strabismus) and uncontrolled blinking (blepharospasm), to treat muscle spasms or movement disorders, and, for the two last decades, more and more often, to provide support in cancer therapy, especially so as to obtain analgesic effects upon spastic conditions. The limited literature data also suggests that the addition of BoNTs to the culture of cancer cell lines reduces cell growth, and mitotic activity, and promotes their apoptosis. BoNTs have several advantages that can be emphasized: BoNTs act on both perfusion and oxygenation; moreover, BoNTs are considered to be safe and free of systemic side effects upon administration. Recently, advances in molecular biology techniques have allowed a wide variety of novel BoNT constructs with alternative functions. These constructs could be assessed as potential new classes of anti-cancer drugs. This creates new potential perspectives in the wider use of non-toxic modified BoNT constructs in cancer therapy. In the light of the mentioned premises and existing literature reports, the aim of this review is to summarize current data and reports considering BoNT use in cancer therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title><jats:italic>Key points<\/jats:italic><\/jats:title><jats:p><jats:italic>\u2022Botulinum toxin (BoNTs) may be useful in cancer treatment.<\/jats:italic><\/jats:p><jats:p><jats:italic>\u2022Botulinum toxin can serve as an analgesic after cancer radiotherapy.<\/jats:italic><\/jats:p><jats:p><jats:italic>\u2022Botulinum toxin has the ability to inhibit tumor growth and promote apoptosis of neoplastic cells.<\/jats:italic><\/jats:p><\/jats:sec>","DOI":"10.1007\/s00253-021-11741-w","type":"journal-article","created":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T09:02:46Z","timestamp":1640336566000},"page":"485-495","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Botulinum toxin in cancer therapy\u2014current perspectives and limitations"],"prefix":"10.1007","volume":"106","author":[{"given":"Tomasz","family":"Grenda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2112-8092","authenticated-orcid":false,"given":"Anna","family":"Grenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Krawczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Kwiatek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,24]]},"reference":[{"issue":"10","key":"11741_CR1","doi-asserted-by":"publisher","first-page":"CD002102","DOI":"10.1002\/14651858.CD002102.pub3","volume":"2018","author":"I Abraha","year":"2018","unstructured":"Abraha I, Aristei C, Palumbo I, Lupattelli M, Trastulli S, Cirocchi R, De Florio R, Valentini V (2018) Preoperative radiotherapy and curative surgery for the management of localised rectal carcinoma. Cochrane Database Syst Rev 2018(10):CD002102. https:\/\/doi.org\/10.1002\/14651858.CD002102.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"11741_CR2","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1158\/1078-0432.CCR-05-1222","volume":"12","author":"R Ansiaux","year":"2006","unstructured":"Ansiaux R, Baudelet C, Cron GO, Segers J, Dessy C, Martinive P, De Wever J, Verrax J, Wauthier V, Beghein N, Gr\u00e9goire V, Calderon PB, Feron O, Gallez B (2006) Botulinum toxin potentiates cancer radiotherapy and chemotherapy. Clin Cancer Res 12:1276\u20131283","journal-title":"Clin Cancer Res"},{"issue":"2","key":"11741_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1517\/13543784.16.2.209","volume":"16","author":"R Ansiaux","year":"2007","unstructured":"Ansiaux R, Gallez B (2007) Use of botulinum toxins in cancer therapy. Expert Opin Investig Drugs 16(2):209\u2013218","journal-title":"Expert Opin Investig Drugs"},{"key":"11741_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.anorl.2011.07.002","volume":"129","author":"CA Bach","year":"2012","unstructured":"Bach CA, Wagner I, Lachiver X, Baujat B, Chabolle F (2012) Botulinum toxin in the treatment of post-radiosurgical neck contracture in head and neck cancer: a novel approach. Eur Ann Otorhinolaryngol Head Neck Dis 129:6\u201310. https:\/\/doi.org\/10.1016\/j.anorl.2011.07.002","journal-title":"Eur Ann Otorhinolaryngol Head Neck Dis"},{"key":"11741_CR5","first-page":"8411","volume":"8","author":"C Bandala","year":"2015","unstructured":"Bandala C, Cort\u00e9s-Algara AL, Mej\u00eda-Barradas CM, Ilizaliturri-Flores I, Dominguez-Rubio R, Baz\u00e1n-M\u00e9ndez CI, Floriano-S\u00e1nchez E, Luna-Arias JP, Anaya-Ruiz M, Lara-Padilla E (2015) Botulinum neurotoxin type A inhibits synaptic vesicle 2 expression in breast cancer cell lines. Int J Clin Exp Pathol 8:8411\u20138418","journal-title":"Int J Clin Exp Pathol"},{"key":"11741_CR6","doi-asserted-by":"publisher","first-page":"891","DOI":"10.7314\/APJCP.2013.14.2.891","volume":"14","author":"C Bandala","year":"2013","unstructured":"Bandala C, Perez-Santos JL, Lara-Padilla E, Delgado Lopez G, Anaya-Ruiz M (2013) Effect of botulinum toxin A on proliferation and apoptosis in the T47D breast cancer cell line. Asian Pac J Cancer Prev 14:891\u2013894. https:\/\/doi.org\/10.7314\/APJCP.2013.14.2.891","journal-title":"Asian Pac J Cancer Prev"},{"key":"11741_CR7","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3390\/toxins11090491","volume":"11","author":"S Bellows","year":"2019","unstructured":"Bellows S, Jankovic J (2019) Immunogenicity Associated with Botulinum Toxin Treatment 11:491. https:\/\/doi.org\/10.3390\/toxins11090491","journal-title":"Immunogenicity Associated with Botulinum Toxin Treatment"},{"key":"11741_CR8","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.2165\/11599840-000000000-00000","volume":"26","author":"R Benecke","year":"2012","unstructured":"Benecke R (2012) Clinical relevance of botulinum toxin immunogenicity. BioDrugs 26:e1\u2013e9. https:\/\/doi.org\/10.2165\/11599840-000000000-00000","journal-title":"BioDrugs"},{"key":"11741_CR9","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1097\/PRS.0000000000002004","volume":"137","author":"JP Bonaparte","year":"2016","unstructured":"Bonaparte JP, Ellis D, Quinn JG, Rabski J, Hutton B (2016) A comparative assessment of three formulations of botulinum toxin type A for facial rhytides: a systematic review with meta-analyses. Plast Reconstr Surg 137:1125\u20131140. https:\/\/doi.org\/10.1097\/PRS.0000000000002004","journal-title":"Plast Reconstr Surg"},{"key":"11741_CR10","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.otohns.2010.04.009","volume":"143","author":"G Cantarella","year":"2010","unstructured":"Cantarella G, Berlusconi A, Mele V, Cogiamanian F, Barbieri S (2010) Treatment of Frey\u2019s syndrome with botulinum toxin type B. Otolaryngol Head Neck Surg 143:214\u2013218. https:\/\/doi.org\/10.1016\/j.otohns.2010.04.009","journal-title":"Otolaryngol Head Neck Surg"},{"key":"11741_CR11","doi-asserted-by":"publisher","first-page":"133","DOI":"10.5603\/PJNNS.a2021.0027","volume":"55","author":"H Car","year":"2021","unstructured":"Car H, Bogucki A, Bonikowski M, Dec-\u0106wiek M, Dru\u017cd\u017c A, Koziorowski D, Rudzi\u0144ska-Bar M, Sarzy\u0144ska-D\u0142ugosz I, S\u0142awek J (2021) Botulinum toxin type-A preparations are not the same medications - basic science (Part 1). Neurol Neurochir Pol 55:133\u2013140. https:\/\/doi.org\/10.5603\/PJNNS.a2021.0027","journal-title":"Neurol Neurochir Pol"},{"key":"11741_CR12","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1111\/j.1524-4725.2005.31206","volume":"31","author":"A Carruthers","year":"2005","unstructured":"Carruthers A, Carruthers J (2005) Prospective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatol Surg 31:1297\u20131303. https:\/\/doi.org\/10.1111\/j.1524-4725.2005.31206","journal-title":"Dermatol Surg"},{"key":"11741_CR13","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/luts.12003","volume":"5","author":"YT Cheng","year":"2013","unstructured":"Cheng YT, Chung YH, Kang HY, Tai MH, Chancellor MB, Chuang YC (2013) OnobotulinumtoxinA has no effects on growth of LNCaP and PC3 human prostate cancer cells. Low Urin Tract Symptoms 5:168\u2013172. https:\/\/doi.org\/10.1111\/luts.12003","journal-title":"Low Urin Tract Symptoms"},{"key":"11741_CR14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3390\/toxins13010058","volume":"13","author":"S Choudhury","year":"2021","unstructured":"Choudhury S, Baker MR, Chatterjee S, Kumar H (2021) Botulinum toxin: an update on pharmacology and newer products in development. Toxins 13:58. https:\/\/doi.org\/10.3390\/toxins13010058","journal-title":"Toxins"},{"key":"11741_CR15","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.3390\/cancers11101472","volume":"11","author":"T Christofi","year":"2019","unstructured":"Christofi T, Baritaki S, Falzone L, Libra M, Zaravinos A (2019) Current perspectives in cancer immunotherapy. Cancers (basel) 11:1472. https:\/\/doi.org\/10.3390\/cancers11101472","journal-title":"Cancers (basel)"},{"key":"11741_CR16","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/mds.870100508","volume":"10","author":"D Claus","year":"1995","unstructured":"Claus D, Druschky A, Erbguth F (1995) Botulinum toxin: influence on respiratory heart rate variation. Mov Disord 10:574\u2013579. https:\/\/doi.org\/10.1002\/mds.870100508","journal-title":"Mov Disord"},{"key":"11741_CR17","doi-asserted-by":"publisher","first-page":"e421","DOI":"10.1016\/j.cllc.2019.02.008","volume":"20","author":"S Clav\u00e9","year":"2019","unstructured":"Clav\u00e9 S, Rodon N, Pijuan L, D\u00edaz O, Lorenzo M, Rocha P, Taus \u00c1, Blanco R, Bosch-Barrera J, Reguart N, de la Torre N, Oliveras G, Espinet B, Bellosillo B, Puig X, Arriola E, Salido M (2019) Next-generation sequencing for ALK and ROS1 rearrangement detection in patients with non-small-cell lung cancer: implications of FISH-positive patterns. Clin Lung Cancer 20:e421\u2013e429. https:\/\/doi.org\/10.1016\/j.cllc.2019.02.008","journal-title":"Clin Lung Cancer"},{"key":"11741_CR18","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/pros.23454","volume":"78","author":"C Coarfa","year":"2018","unstructured":"Coarfa C, Florentin D, Putluri N, Ding Y, Au J, He D, Ragheb A, Frolov A, Michailidis G, Lee M, Kadmon D, Miles B, Smith C, Ittmann M, Rowley D, Sreekumar A, Creighton CJ, Ayala G (2018) Influence of the neural microenvironment on prostate cancer. Prostate 78:128\u2013139. https:\/\/doi.org\/10.1002\/pros.23454","journal-title":"Prostate"},{"key":"11741_CR19","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1212\/01.wnl.0000345010.98495.fc","volume":"72","author":"A Curr\u00e0","year":"2009","unstructured":"Curr\u00e0 A, Berardelli A (2009) Do the unintended actions of botulinum toxin at distant sites have clinical implications? Neurology 72:1095\u20131099. https:\/\/doi.org\/10.1212\/01.wnl.0000345010.98495.fc","journal-title":"Neurology"},{"key":"11741_CR20","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2147\/cia.s9338","volume":"5","author":"K De Boulle","year":"2010","unstructured":"De Boulle K, Fagien S, Sommer B, Glogau R (2010) Treating glabellar lines with botulinum toxin type A-hemagglutinin complex: a review of the science, the clinical data, and patient satis-faction. Clin Interv Aging 5:101\u2013118. https:\/\/doi.org\/10.2147\/cia.s9338","journal-title":"Clin Interv Aging"},{"key":"11741_CR21","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.apmr.2017.12.032","volume":"99","author":"A De Groef","year":"2018","unstructured":"De Groef A, Devoogdt N, Van Kampen M, Nevelsteen I, Smeets A, Neven P, Geraerts I, Dams L, Van der Gucht E, Debeer P (2018) Effectiveness of botulinum toxin A for persistent upper limb pain after breast cancer treatment: a double-blinded randomized controlled trial. Arch Phys Med Rehabil 99:1342\u20131351. https:\/\/doi.org\/10.1016\/j.apmr.2017.12.032","journal-title":"Arch Phys Med Rehabil"},{"key":"11741_CR22","doi-asserted-by":"publisher","first-page":"S92","DOI":"10.1002\/mds.20022","volume":"19","author":"D Dressler","year":"2004","unstructured":"Dressler D (2004) Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord 19:S92\u2013S100","journal-title":"Mov Disord"},{"issue":"10","key":"11741_CR23","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s00702-019-02029-5","volume":"126","author":"D Dressler","year":"2019","unstructured":"Dressler D, Kollewe K, Kruger THC, Gade N, Sikorra S, Bigalke H (2019) Botulinum toxin type D blocks autonomic cholinergic synapses in humans: discussion of a potential therapeutic use. J Neural Transm (vienna) 126(10):1337\u20131340. https:\/\/doi.org\/10.1007\/s00702-019-02029-5","journal-title":"J Neural Transm (vienna)"},{"key":"11741_CR24","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1590\/S0004-282X2005000100035","volume":"63","author":"D Dressler","year":"2005","unstructured":"Dressler D, Saberi FA, Barbosa ER (2005) Botulinum toxin: mechanisms of action. Arq Neuropsiquiatr 63:180\u2013185","journal-title":"Arq Neuropsiquiatr"},{"key":"11741_CR25","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.toxicon.2010.12.019","volume":"57","author":"KH Eisele","year":"2011","unstructured":"Eisele KH, Fink K, Vey M, Taylor HV (2011) Studies on the dissociation of botulinum neuro-toxin type A complexes. Toxicon 57:555\u2013565. https:\/\/doi.org\/10.1016\/j.toxicon.2010.12.019","journal-title":"Toxicon"},{"key":"11741_CR26","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.toxicon.2020.02.020","volume":"179","author":"R Eleopra","year":"2020","unstructured":"Eleopra R, Rinaldo S, Montecucco C, Rossetto O, Devigili G (2020) Clinical duration of action of different botulinum toxin types in humans. Toxicon 179:84\u201391. https:\/\/doi.org\/10.1016\/j.toxicon.2020.02.020","journal-title":"Toxicon"},{"key":"11741_CR27","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s12640-015-9565-5","volume":"29","author":"M Fabbri","year":"2016","unstructured":"Fabbri M, Leodori G, Fernandes RM, Bhidayasiri R, Marti MJ, Colosimo C, Ferreira JJ (2016) Neutralizing antibody and botulinum toxin therapy: a systematic review and meta-analysis. Neurotox Res 29:105\u2013117","journal-title":"Neurotox Res"},{"key":"11741_CR28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.11138\/fneur\/2018.33.1.007","volume":"33","author":"A Ferrari","year":"2018","unstructured":"Ferrari A, Manca M, Tugnoli V, Alberto L (2018) Pharmacological differences and clinical implica-tions of various botulinum toxin preparations: a critical appraisal. Funct. Neurol 33:7\u201318. https:\/\/doi.org\/10.11138\/fneur\/2018.33.1.007","journal-title":"Funct. Neurol"},{"key":"11741_CR29","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3390\/toxins10070278","volume":"10","author":"E Fonfria","year":"2018","unstructured":"Fonfria E, Elliott M, Beard M, Chaddock JA, Krupp J (2018) Engineering botulinum toxins to improve and expand targeting and SNARE cleavage activity. Toxins 10:278. https:\/\/doi.org\/10.3390\/toxins10070278","journal-title":"Toxins"},{"key":"11741_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40268-014-0077-1","volume":"15","author":"J Frevert","year":"2015","unstructured":"Frevert J (2015) Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products. Drugs r d 15:1\u20139. https:\/\/doi.org\/10.1007\/s40268-014-0077-1","journal-title":"Drugs r d"},{"key":"11741_CR31","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2147\/BTT.S14902","volume":"4","author":"J Frevert","year":"2010","unstructured":"Frevert J, Dressler D (2010) Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? Biologics 4:325\u2013332. https:\/\/doi.org\/10.2147\/BTT.S14902","journal-title":"Biologics"},{"key":"11741_CR32","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/0360-3016(94)00422-H","volume":"31","author":"EL Gillette","year":"1995","unstructured":"Gillette EL, Mahler PA, Powers BE, Gillette SM, Vujaskovic Z (1995) Late radiation injury to muscle and peripheral nerves. Int J Radiat Oncol Biol Phys 31:1309\u20131318. https:\/\/doi.org\/10.1016\/0360-3016(94)00422-H","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"11741_CR33","doi-asserted-by":"publisher","first-page":"4994","DOI":"10.21037\/jtd.2018.07.28","volume":"10","author":"A Grenda","year":"2018","unstructured":"Grenda A, Jarosz B, Krawczyk P, Kucharczyk T, Wojas-Krawczyk K, Reszka K, Krukowska K, Nico\u015b M, Pankowski J, Bryl M, Ramlau R, Ku\u017anar-Kami\u0144ska B, Grodzki T, Szcz\u0119sna A, Siemi\u0105tkowska K, Szumi\u0142o J, Batura-Gabryel H, Palonka M, Milanowski J (2018) Discrepancies between ALK protein disruption and occurrence of ALK gene rearrangement in Polish NSCLC patients. J Thorac Dis. 10:4994\u20135009. https:\/\/doi.org\/10.21037\/jtd.2018.07.28","journal-title":"J Thorac Dis."},{"key":"11741_CR34","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1515\/jvetres-2017-0038","volume":"61","author":"T Grenda","year":"2017","unstructured":"Grenda T, Grabczak M, Kwiatek K, Bober A (2017) Prevalence of C. Botulinum and C. Perfringens spores in food products available on Polish market. J Vet Res 61:287\u2013291. https:\/\/doi.org\/10.1515\/jvetres-2017-0038","journal-title":"J Vet Res"},{"key":"11741_CR35","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/978-3-642-33570-9_2","volume":"364","author":"S Gu","year":"2013","unstructured":"Gu S, Jin R (2013) Assembly and function of the botulinum neurotoxin progenitor complex. Curr Top Microbiol Immunol 364:21\u201344. https:\/\/doi.org\/10.1007\/978-3-642-33570-9_2","journal-title":"Curr Top Microbiol Immunol"},{"key":"11741_CR36","doi-asserted-by":"publisher","first-page":"5977","DOI":"10.7314\/APJCP.2015.16.14.5977","volume":"16","author":"S Hajighasemlou","year":"2015","unstructured":"Hajighasemlou S, Alebouyeh M, Ra\u00e4egar H, Manzari MT, Mirmoghtadaei M, Moayedi B, Ahmadzadeh M, Parvizpour F, Johari B, Naeini MM, Farajollahi MM (2015) Preparation of immunotoxin herceptin-botulinum and killing effects on two breast cancer cell lines. Asian Pac J Cancer Prev 16:5977\u20135981. https:\/\/doi.org\/10.7314\/APJCP.2015.16.14.5977","journal-title":"Asian Pac J Cancer Prev"},{"key":"11741_CR37","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.toxicon.2017.08.011","volume":"147","author":"M Hallett","year":"2018","unstructured":"Hallett M (2018) Mechanism of action of botulinum neurotoxin: unexpected consequences. Toxicon 147:73\u201376","journal-title":"Toxicon"},{"key":"11741_CR38","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.humpath.2016.02.001","volume":"52","author":"D He","year":"2016","unstructured":"He D, Manzoni A, Florentin D, Fisher W, Ding Y, Lee M, Ayala G (2016) Biologic effect of neurogenesis in pancreatic cancer. Hum Pathol 52:182\u2013189. https:\/\/doi.org\/10.1016\/j.humpath.2016.02.001","journal-title":"Hum Pathol"},{"key":"11741_CR39","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1210\/mend.12.7.0130","volume":"12","author":"X Huang","year":"1998","unstructured":"Huang X, Wheeler MB, Kang YH, Sheu L, Lukacs GL, Trimble WS, Gaisano HY (1998) Truncated SNAP-25 (1\u2013197), like botulinum neurotoxin A, can inhibit insulin secretion from HIT-T15 insulinoma cells. Mol Endocrinol 12:1060\u20131070. https:\/\/doi.org\/10.1210\/mend.12.7.0130","journal-title":"Mol Endocrinol"},{"key":"11741_CR40","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/978-1-4939-2501-8","volume-title":"Botulinum toxin treatment of pain disorders","author":"B Jabbari","year":"2015","unstructured":"Jabbari B (2015) Botulinum toxin treatment of pain disorders, 1st edn. Springer and Bussines Media, New York, pp 2\u20134","edition":"1"},{"key":"11741_CR41","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1002\/pros.20958","volume":"69","author":"G Karsenty","year":"2009","unstructured":"Karsenty G, Rocha J, Chevalier S, Scarlata E, Andrieu C, Zouanat FZ, Rocchi P, Giusiano S, Elzayat EA, Corcos J (2009) Botulinum toxin type A inhibits the growth of LNCaP human prostate cancer cells in vitro and in vivo. Prostate 69:1143\u20131150. https:\/\/doi.org\/10.1002\/pros.20958","journal-title":"Prostate"},{"key":"11741_CR42","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1016\/S0140-6736(06)68700-X","volume":"367","author":"H Kehlet","year":"2006","unstructured":"Kehlet H, Jensen TS, Woolf CJ (2006) Persistent postsurgical pain: risk factors and prevention. Lancet 367:1618\u20131625. https:\/\/doi.org\/10.1016\/S0140-6736(06)68700-X","journal-title":"Lancet"},{"key":"11741_CR43","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s10006-012-0375-0","volume":"17","author":"R Laskawi","year":"2013","unstructured":"Laskawi R, Winterhoff J, K\u00f6hler S, Kottwitz L, Matthias C (2013) Botulinum toxin treatment of salivary fistulas following parotidectomy: follow-up results. Oral Maxillofac Surg 17:281\u2013285. https:\/\/doi.org\/10.1007\/s10006-012-0375-0","journal-title":"Oral Maxillofac Surg"},{"key":"11741_CR44","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1097\/01.sla.0000141156.56314.1f","volume":"240","author":"R Layeeque","year":"2004","unstructured":"Layeeque R, Hochberg J, Siegel E, Kunkel K, Kepple J, Henry-Tillman RS, Dunlap M, Seibert J, Klimberg VS (2004) Botulinum toxin infiltration for pain control after mastectomy and expander reconstruction. Ann Surg 240:608\u2013613. https:\/\/doi.org\/10.1097\/01.sla.0000141156.56314.1f","journal-title":"Ann Surg"},{"key":"11741_CR45","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.jaad.2011.10.008","volume":"67","author":"A Liu","year":"2012","unstructured":"Liu A, Carruthers A, Cohen JL, Coleman WP 3rd, Dover JS, Hanke CW, Moy RL, Ozog DM (2012) Recommendations and current practices for the reconstitution and storage of botulinum toxin type A. J Am Acad Dermatol 67:373\u2013378. https:\/\/doi.org\/10.1016\/j.jaad.2011.10.008","journal-title":"J Am Acad Dermatol"},{"key":"11741_CR46","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3390\/toxins11080472","volume":"11","author":"B Maikanov","year":"2019","unstructured":"Maikanov B, Mustafina R, Auteleyeva L, Wi\u015bniewski J, Anusz K, Grenda T, Kwiatek K, Goldsztejn M, Grabczak M (2019) Clostridium botulinum and Clostridium perfringens occurrence in Kazakh honey samples. Toxins (basel) 11:472. https:\/\/doi.org\/10.3390\/toxins11080472","journal-title":"Toxins (basel)"},{"key":"11741_CR47","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.canrad.2019.02.001","volume":"23","author":"M Mailly","year":"2019","unstructured":"Mailly M, Benzakin S, Chauvin A, Brasnu D, Ayache D (2019) Douleurs post-radiques apr\u00e8s radioth\u00e9rapie pour cancer des voies a\u00e9rodigestives superieures: Traitement par injections de toxine botulique A [Radiation-induced head and neck pain: management with botuli-num toxin a injections]. Cancer Radiother 23:312\u2013315. https:\/\/doi.org\/10.1016\/j.canrad.2019.02.001","journal-title":"Cancer Radiother"},{"key":"11741_CR48","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3390\/toxins11080459","volume":"11","author":"I Matak","year":"2019","unstructured":"Matak I, B\u00f6lcskei K, Bach-Rojecky L, Helyes Z (2019) Mechanisms of botulinum toxin type A action on pain. Toxins (basel) 11:459. https:\/\/doi.org\/10.3390\/toxins11080459","journal-title":"Toxins (basel)"},{"key":"11741_CR49","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1111\/j.1526-4637.2012.01437.x","volume":"13","author":"S Mittal","year":"2012","unstructured":"Mittal S, Machado DG, Jabbari B (2012) OnabotulinumtoxinA for treatment of focal cancer pain after surgery and\/or radiation. Pain Med 13:1029\u20131033. https:\/\/doi.org\/10.1111\/j.1526-4637.2012.01437.x","journal-title":"Pain Med"},{"key":"11741_CR50","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3390\/toxins12010032","volume":"12","author":"SO Mittal","year":"2020","unstructured":"Mittal SO, Jabbari B (2020) Botulinum neurotoxins and cancer\u2014a review of the literature. Toxins (basel) 12:32. https:\/\/doi.org\/10.3390\/toxins12010032","journal-title":"Toxins (basel)"},{"key":"11741_CR51","unstructured":"National Cancer Registration & Analysis Service and Cancer Research UK: \"Chemotherapy, Radiotherapy and Tumour Resections in England: 2013\u20132014\" workbook London: NCRAS; 2017"},{"key":"11741_CR52","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","volume":"17","author":"DY Oh","year":"2020","unstructured":"Oh DY, Bang YJ (2020) HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol 17:33\u201348. https:\/\/doi.org\/10.1038\/s41571-019-0268-3","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"11741_CR53","doi-asserted-by":"publisher","first-page":"260","DOI":"10.3390\/toxins9090260","volume":"9","author":"J Park","year":"2017","unstructured":"Park J, Park HJ (2017) Botulinum toxin for the treatment of neuropathic pain. Toxins (basel) 9(9):260. https:\/\/doi.org\/10.3390\/toxins9090260","journal-title":"Toxins (basel)"},{"key":"11741_CR54","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s00266-006-0161-1","volume":"31","author":"AA Parsa","year":"2007","unstructured":"Parsa AA, Lye KD, Parsa FD (2007) Reconstituted botulinum type A neurotoxin: clinical efficacy after long-term freezing before use. Aesth Plast Surg 31:188\u2013191. https:\/\/doi.org\/10.1007\/s00266-006-0161-1","journal-title":"Aesth Plast Surg"},{"key":"11741_CR55","doi-asserted-by":"publisher","unstructured":"Pero R, Laneri S, Fico, G (2018) Botulinum toxin adverse events. Botulinum Toxin, Edited by Nikolay Serdev. INTECHOPEN LIMITED. London. https:\/\/doi.org\/10.5772\/intechopen.73809","DOI":"10.5772\/intechopen.73809"},{"key":"11741_CR56","doi-asserted-by":"publisher","unstructured":"Pickett A (2014) Botulinum toxin as a clinical product: manufacture and pharmacology. In: Foster K. (eds) Clinical Applications of Botulinum Neurotoxin. Current Topics in Neurotoxicity, vol 5. Springer, New York, NY. https:\/\/doi.org\/10.1007\/978-1-4939-0261-3_2","DOI":"10.1007\/978-1-4939-0261-3_2"},{"key":"11741_CR57","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1124\/pr.116.012658","volume":"69","author":"M Pirazzini","year":"2017","unstructured":"Pirazzini M, Rossetto O, Eleopra R, Montecucco C (2017) Botulinum neurotoxins: biology, pharmacology, and toxicology. Pharmacol Rev 69:200\u2013235. https:\/\/doi.org\/10.1124\/pr.116.012658","journal-title":"Pharmacol Rev"},{"key":"11741_CR58","doi-asserted-by":"publisher","first-page":"135","DOI":"10.5301\/RU.2012.9254","volume":"79","author":"S Proietti","year":"2012","unstructured":"Proietti S, Nardicchi V, Porena M, Giannantoni A (2012) Attivit\u00e0 della tossina botulinica A in linee cellulari di cancro prostatico [Botulinum toxin type-A toxin activity on prostate cancer cell lines]. Urologia 79:135\u2013141. https:\/\/doi.org\/10.5301\/RU.2012.9254","journal-title":"Urologia"},{"key":"11741_CR59","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/nrmicro3295","volume":"12","author":"O Rossetto","year":"2014","unstructured":"Rossetto O, Pirazzini M, Montecucco C (2014) Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat Rev Microbiol 12:535\u2013549. https:\/\/doi.org\/10.1038\/nrmicro3295","journal-title":"Nat Rev Microbiol"},{"key":"11741_CR60","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/toxins8010022","volume":"8","author":"R Rostami","year":"2016","unstructured":"Rostami R, Mittal SO, Radmand R, Jabbari B (2016) Incobotulinum Toxin-A improves post-surgical and post-radiation pain in cancer patients. Toxins (basel) 8:22. https:\/\/doi.org\/10.3390\/toxins8010022","journal-title":"Toxins (basel)"},{"key":"11741_CR61","doi-asserted-by":"publisher","first-page":"33220","DOI":"10.18632\/oncotarget.8903","volume":"7","author":"A Rust","year":"2016","unstructured":"Rust A, Leese C, Binz T, Davletov B (2016) Botulinum neurotoxin type C protease induces apoptosis in differentiated human neuroblastoma cells. Oncotarget 7:33220\u201333228. https:\/\/doi.org\/10.18632\/oncotarget.8903","journal-title":"Oncotarget"},{"key":"11741_CR62","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.toxicon.2018.01.017","volume":"147","author":"Y Safarpour","year":"2018","unstructured":"Safarpour Y, Jabbari B (2018) Botulinum toxin treatment of pain syndromes\u2014an evidence based review. Toxicon 147:120\u2013128. https:\/\/doi.org\/10.1016\/j.toxicon.2018.01.017","journal-title":"Toxicon"},{"key":"11741_CR63","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2147\/CCID.S156851","volume":"11","author":"S Samizadeh","year":"2018","unstructured":"Samizadeh S, De Boulle K (2018) Botulinum neurotoxin formulations: overcoming the confusion. Clin Cosmet Investig Dermatol 11:273\u2013287. https:\/\/doi.org\/10.2147\/CCID.S156851","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"11741_CR64","first-page":"40","volume":"10","author":"L Shaw","year":"2019","unstructured":"Shaw L, Bazzell AF, Dains JE (2019) Botulinum toxin for side-effect management and prevention of surgical complications in patients treated for head and neck cancers and esophageal cancer. J Adv Pract Oncol 10:40\u201352","journal-title":"J Adv Pract Oncol"},{"key":"11741_CR65","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.22037\/ijpr.2019.1100800","volume":"18","author":"RI Shebl","year":"2019","unstructured":"Shebl RI (2019) Anti-cancer potential of captopril and botulinum toxin type-A and associated p53 gene apototic stimulating activity. Iran J Pharm Res. Fall 18:1967\u20131977. https:\/\/doi.org\/10.22037\/ijpr.2019.1100800","journal-title":"Iran J Pharm Res. Fall"},{"key":"11741_CR66","first-page":"6627","volume":"34","author":"A Steffen","year":"2014","unstructured":"Steffen A, Hasselbacher K, Heinrichs S, Wollenberg B (2014) Botulinum toxin for salivary disorders in the treatment of head and neck cancer. Anticancer Res 34:6627\u20136632","journal-title":"Anticancer Res"},{"key":"11741_CR67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0119707","volume":"10","author":"F Ulloa","year":"2015","unstructured":"Ulloa F, Gonz\u00e0lez-Junc\u00e0 A, Meffre D, Barrecheguren PJ, Mart\u00ednez-M\u00e1rmol R, Pazos I, Oliv\u00e9 N, Cotrufo T, Seoane J (2015) Soriano E (2015) Blockade of the SNARE protein syntaxin 1 inhibits glioblastoma tumor growth. PLoS ONE 10:e0119707. https:\/\/doi.org\/10.1371\/journal.pone.0119707","journal-title":"PLoS ONE"},{"key":"11741_CR68","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1001\/archotol.128.8.956","volume":"128","author":"DJ Van Daele","year":"2002","unstructured":"Van Daele DJ, Finnegan EM, Rodnitzky RL, Zhen W, McCulloch TM, Hoffman HT (2002) Head and neck muscle spasm after radiotherapy: management with botulinum toxin A in-jection. Arch Otolaryngol Head Neck Surg 128:956\u2013959. https:\/\/doi.org\/10.1001\/archotol.128.8.956","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"11741_CR69","first-page":"239","volume":"8","author":"K Vezdrevanis","year":"2011","unstructured":"Vezdrevanis K (2011) Prostatic carcinoma shrunk after intraprostatic injection of botulinum toxin. Urol J 8:239\u2013241","journal-title":"Urol J"},{"key":"11741_CR70","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/toxins11010021","volume":"11","author":"D Weise","year":"2019","unstructured":"Weise D, Weise CM, Naumann M (2019) Central effects of botulinum neurotoxin \u2013 evidence from human studies. Toxins 11:21. https:\/\/doi.org\/10.3390\/toxins11010021","journal-title":"Toxins"},{"key":"11741_CR71","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/s41417-020-0167-x","volume":"27","author":"J Whitt","year":"2020","unstructured":"Whitt J, Hong WS, Telange RR, Lin CP, Bibb J, Beebe DJ, Chen H, Jaskula-Sztul R (2020) Non-toxic fragment of botulinum neurotoxin type A and monomethyl auristatin E conju-gate for targeted therapy for neuroendocrine tumors. Cancer Gene Ther 27:898\u2013909. https:\/\/doi.org\/10.1038\/s41417-020-0167-x","journal-title":"Cancer Gene Ther"},{"key":"11741_CR72","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1097\/01.mlg.0000217797.05523.75","volume":"116","author":"C Wittekindt","year":"2006","unstructured":"Wittekindt C, Liu WC, Preuss SF, Guntinas-Lichius O (2006) Botulinum toxin A for neuro-pathic pain after neck dissection: a dose-finding study. Laryngoscope 116:1168\u20131171. https:\/\/doi.org\/10.1097\/01.mlg.0000217797.05523.75","journal-title":"Laryngoscope"},{"key":"11741_CR73","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2165\/00128071-200506030-00001","volume":"6","author":"U Wollina","year":"2005","unstructured":"Wollina U, Konrad H (2005) Managing adverse events associated with botulinum toxin type A. Am J Clin Dermatol 6:141\u2013150. https:\/\/doi.org\/10.2165\/00128071-200506030-00001","journal-title":"Am J Clin Dermatol"},{"key":"11741_CR74","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.1128\/AEM.07568-11","volume":"78","author":"C Woudstra","year":"2012","unstructured":"Woudstra C, Skarin H, Anniballi F, Fenicia L, Bano L, Drigo I, Koene M, B\u00e4yon-Auboyer MH, Buffereau JP, De Medici D, Fach P (2012) Neurotoxin gene profiling of Clostridium botulinum types C and D native to different countries within Europe. Appl Environ Microbiol 78:3120\u20133127. https:\/\/doi.org\/10.1128\/AEM.07568-11","journal-title":"Appl Environ Microbiol"},{"key":"11741_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.654387","volume":"19","author":"S Wu","year":"2021","unstructured":"Wu S, Shi X, Ren X, Li K, Pang J, Liang Z (2021) Evaluation of NTRK gene fusion by five different platforms in triple-negative breast carcinoma. Front Mol Biosci 19:654387. https:\/\/doi.org\/10.3389\/fmolb.2021.654387","journal-title":"Front Mol Biosci"},{"key":"11741_CR76","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1001\/archfaci.10.4.273","volume":"10","author":"GC Yang","year":"2008","unstructured":"Yang GC, Chiu RJ, Gillman G (2008) Questioning the need to use Botox within 4 hours of reconstitution; a study of fresh vs 2-week-old Botox. JAMA Facial Plastic Surgery 10:273\u2013279","journal-title":"JAMA Facial Plastic Surgery"},{"key":"11741_CR77","doi-asserted-by":"publisher","first-page":"847e","DOI":"10.1097\/PRS.0000000000005029","volume":"142","author":"SG Yoelin","year":"2018","unstructured":"Yoelin SG, Dhawan SS, Vitarella D, Ahmad W, Hasan F, Abushakra S (2018) Safety and efficacy of EB-001, a novel type E botulinum toxin, in subjects with glabellar frown lines: Results of a phase 2, randomized, placebo-controlled, ascending-dose study. Plast Reconstr Surg 142:847e\u2013855e","journal-title":"Plast Reconstr Surg"}],"container-title":["Applied Microbiology and Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00253-021-11741-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00253-021-11741-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00253-021-11741-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T11:08:59Z","timestamp":1674212939000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00253-021-11741-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,24]]},"references-count":77,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["11741"],"URL":"https:\/\/doi.org\/10.1007\/s00253-021-11741-w","relation":{},"ISSN":["0175-7598","1432-0614"],"issn-type":[{"value":"0175-7598","type":"print"},{"value":"1432-0614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,24]]},"assertion":[{"value":"28 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}